INNOVIVA, INC. Payments for Purchase of Securities, Operating Activities
INNOVIVA, INC. (INVA) reported Payments for Purchase of Securities, Operating Activities of $43.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities · last filed 2026-08-05
- INNOVIVA, INC. payments for purchase of securities, operating activities for the quarter ending 2026-06-30 was $27.36M.
- INNOVIVA, INC. payments for purchase of securities, operating activities for the quarter ending 2026-03-31 was $15.84M, a 54.32% decline year-over-year.
- INNOVIVA, INC. payments for purchase of securities, operating activities for the quarter ending 2025-12-31 was $12.05M, a 7.09% decline year-over-year.
- INNOVIVA, INC. payments for purchase of securities, operating activities for the quarter ending 2025-09-30 was $15.00M.
- INNOVIVA, INC. payments for purchase of securities, operating activities for fiscal 2024 was $63.20M, a 6.78% decline from fiscal 2023.
- INNOVIVA, INC. payments for purchase of securities, operating activities for fiscal 2023 was $67.80M.
| Period end | Payments for Purchase of Securities, Operating Activities 3 month | Payments for Purchase of Securities, Operating Activities 6 month | Payments for Purchase of Securities, Operating Activities 9 month | Payments for Purchase of Securities, Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $43.20M 10-Q · filed 2026-08-05 | $55.26M derived: sum of 3 quarters · filed 2026-08-05 | $70.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $15.84M 10-Q · filed 2026-05-06 | $27.89M derived: sum of 2 quarters · filed 2026-08-05 | $42.90M derived: sum of 3 quarters · filed 2026-08-05 | $42.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $12.05M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-05 | $27.05M derived: sum of 2 quarters · filed 2026-08-05 | $27.05M derived: sum of 3 quarters · filed 2026-08-05 | $61.73M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.00M derived: sum of 2 quarters · filed 2025-11-05 | $49.67M 10-Q · filed 2025-11-05 | $62.65M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $34.67M 10-Q · filed 2025-08-06 | $47.65M derived: sum of 3 quarters · filed 2026-02-25 | |
| 2025-03-31 | $34.67M 10-Q · filed 2025-05-07 | $47.65M derived: sum of 2 quarters · filed 2026-02-25 | ||
| 2024-12-31 | $12.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $63.20M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $50.23M 10-Q · filed 2024-11-06 | |||
| 2023-12-31 | $67.80M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |